THE few studies on the levels of the major immunoglobulin classes (IgA, 
IgG and IgM) in breast cancer patients have yielded different results. For instance, Hughes (1971) found serum IgA levels to be no higher than those in control subjects. Dostalova et al. (1970) and Rowinska-Zakrewska, Lazar and Burtin (1970) , on the other hand, reported raised levels of IgA, as did Roberts, Bathgate and Stevenson (1.975) Estimations of immunoglobulins in this study were made by the same method, using the same IDP Sevac.
Results in different cancer groups and controls were compared and analysed by Student's t test, with P < 0 05 as the level of significance.
Mean immunoglobulin values are ranged in the Table according to immunoglobulin class and to the stage of the disease.
IgA. Significantly higher levels are found in Groups (c) and (d) than in the controls. There is also a significant difference between Groups (a) and (d).
IgG. There is a statistically significant difference between Group (c) and controls but not between other cancer groups.
IgM.-There are no significant differences between any of the groups.
IgD. In all cancer groups, significantly lower levels were found than in We think that locally advanced disease (T3-4N0M0 and T3-4NIaM0 with the reservation mentioned above) seems to constitute a biologically distinct group. The tumours grow locally without apparent tendency to disseminate, but it is not clear whether this is caused by tumour quality or by the ability of the host to confine the tumour. We did not therefore combine this series with any other, despite the small number in this classification.
We have confirmed the findings of most authors, of raised IgA levels in breast cancer patients. We have found elevated levels of IgA in all stages of the disease, which is in accordance with findings of Roberts et al. (1975) (Levy et al., 1975; Brown et al., 1975; Zeromski et al., 1975; O'Neill and Romsdahl, 1974) and to the recent theories that immune exclusion is a function of IgA (Stiehm, 1973; Stokes, Soothill and Turner, 1975) .
Our results for IgG are, on the whole, in agreement with most authors, who found the levels to be normal. Although mean IgG levels in advanced series are elevated (in one group there is a significant difference from the controls), most of the results are within the normal range.
The role of 1gD in the human immune response has not been clearly defined.
Therefore we cannot speculate at present on the lower IgD levels found in all stages of breast cancer patients. IgA levels are of more importance. Meyer et al. (1973) reported that post-mastectomy irradiation was detrimental to patients with a low IgA concentration, and might improve survival in women with a high preoperative level. Taking these findings into account we believe that the prognostic value of changes in IgA levels may not be so indicative as our data might lead us to suppose.
We thank Dr J. Bystry for help with mathematical evaluation.
